4.1 Review

Treatment of Irritable Bowel Syndrome With Comorbid Anxiety Symptoms With Mirtazapine

期刊

CLINICAL NEUROPHARMACOLOGY
卷 34, 期 1, 页码 36-38

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WNF.0b013e318209cef2

关键词

mirtazapine; irritable bowel syndrome; serotonin receptor type-3; anxiety

向作者/读者索取更多资源

Irritable bowel syndrome (IBS) is a functional gastrointestinal tract disorder characterized by recurrent abdominal pain or discomfort, where the onset is associated with either a change in form of stool or its frequency and is often improved with defecation. Alosetron, a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, was an effective drug in treating women with diarrhea-predominant IBS. However, the drug was removed from the United States market because of its association with ischemic colitis and serious complications related to severe constipation. Presented here is a case report of a 66-year-old woman with a history of panic disorder and major depression and a 1-year history of IBS-mixed type, which she reported to be worsened by panic attacks. On the basis that mirtazapine is a potent 5-HT3 receptor antagonist and has demonstrated pain relief from somatic symptoms, we treated our patient with mirtazapine, which seems to have decreased her diarrhea and constipation symptoms, and her psychopathological symptoms.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据